Moderna, Inc.

(NASDAQ Global Select)
Back to all articles
Bullish +55

Moderna Jumps 7% While Melanoma Vaccine Data Looms; Bristol Myers Squibb Rises 5%, Pfizer Advances 2%

Clinical trial results Drug approval AI-generated analysis

πŸ“ˆ Moderna stock jumped 7% to $241.89 ahead of critical melanoma trial data expected on October 24.

πŸ’Š The upcoming study tests intismeran combined with Merck's Keytruda, showing a 49% risk reduction in recurrence or death from Phase 2b data.

πŸ“‰ Moderna reported Q2 revenue of $145 million and a net loss of $782 million, creating high sensitivity to pipeline outcomes.

🏭 The company is building dedicated manufacturing facilities in Massachusetts to support the potential launch of intismeran.

πŸ”¬ Phase 3 study results require a minimum of 18 months of follow-up, with overall survival data still pending evaluation.

πŸ“Š Moderna holds only 0.4% of assets in the Health Care Select Sector SPDR ETF (XLV), making its stock move distinct from larger peers like Merck.

⚠️ Investors face binary risk as a shortfall in data could pressure shares, while confirmation could extend the recent rally.

Bullish Signals
  • Shares surged 7% to $241.89 ahead of anticipated positive late-stage melanoma trial data presentation on October 24.
  • Previous Phase 2b data demonstrated a 49% reduction in the risk of recurrence or death when combining intismeran with Keytruda versus Keytruda alone.
  • Management confirmed manufacturing infrastructure in Massachusetts is being established to support the commercial launch of intismeran.
  • The company reiterated its financial outlook for up to 10% revenue growth in 2026 despite current losses.
Risk Factors
  • Q2 results showed only $145 million in revenue against a massive $782 million net loss, leaving the stock heavily dependent on pipeline wins.
  • Overall survival data for the melanoma combination therapy is still under evaluation and has not yet been confirmed.
  • The company faces significant binary risk where a shortfall in the October 24 data could cause sharp downward pressure on shares.
Full Analysis
Moderna (MRNA) shares surged approximately 6-7% to $241.89, significantly outpacing the broader healthcare sector and Dow Jones Industrial Average, driven by anticipation of late-stage melanoma trial data scheduled for presentation on October 24 in Madrid. The upcoming results will evaluate the combination of intismeran plus Merck's Keytruda against Keytruda alone following surgery, a program that previously demonstrated a 49% reduction in the risk of recurrence or death during Phase 2b. The stock rally highlights Moderna's heavy dependence on its cancer pipeline to offset weak core business performance. In Q2, the company reported revenue of $145 million against a substantial net loss of $782 million, leaving it with limited financial buffer if the upcoming data disappoints. Management has confirmed manufacturing capabilities in Massachusetts are being established to support a potential launch of intismeran as its first cancer product. Analysts and investors are closely watching whether the full data presented on October 24 will match previously announced improvements in recurrence-free and distant-metastasis-free survival, with overall survival still under evaluation. The company maintains an outlook for up to 10% revenue growth in 2026, but shares could face sharp volatility depending on whether the Phase 3 study confirms these benefits or if management's confidence holds during the investor webcast.